Cargando…
The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
BACKGROUND: Body composition is an important predictor of drug toxicity and outcome. Ipilimumab (Ipi), a monoclonal antibody used to treat metastatic melanoma, has specific toxicities. No validated biomarkers that predict Ipi toxicity and efficacy exist. Also, the impact of Ipi on body composition h...
Autores principales: | Daly, Louise E, Power, Derek G, O'Reilly, Áine, Donnellan, Paul, Cushen, Samantha J, O'Sullivan, Kathleen, Twomey, Maria, Woodlock, David P, Redmond, Henry P, Ryan, Aoife M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294486/ https://www.ncbi.nlm.nih.gov/pubmed/28072766 http://dx.doi.org/10.1038/bjc.2016.431 |
Ejemplares similares
-
Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015) -
Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer
por: Daly, Louise E., et al.
Publicado: (2018) -
Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022) -
The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma
por: Khoja, Leila, et al.
Publicado: (2016) -
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)